All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers from Shanghai Institute of Materia Medica presented the discovery of novel furan-2-carboxylic acid derivatives as potential candidates for the treatment of type 2 diabetes mellitus (T2DM). Synthesis and optimization of SL-010110, a previously identified molecule with the ability to inhibit gluconeogenesis via a unique mechanism, resulted in the discovery of a novel series of derivatives.
Researchers from Shanghai Institute of Materia Medica and affiliated organizations recently reported the synthesis and evaluation of novel α-pyrone III derivatives as potential therapeutic agents for the treatment of atherosclerosis.
Evidence has suggested free fatty acid receptor 1 (FFAR1), also known as GPR40, as a promising therapeutic target in the treatment of type 2 diabetes, since its activation in pancreatic β cells promotes insulin secretion in a glucose concentration-dependent manner.
Blood vessels supplying adipose tissue in females and males differed in their biological characteristics and gene expression programs, researchers at York University in Toronto, Canada, have demonstrated. The findings, which will appear in the Jan. 20, 2023, print issue of Iscience after earlier publication online, give new insights into sex differences in metabolic health.
Fat tissue can be detrimental to health, but the relationship between fat, BMI and health is increasingly acknowledged as being highly complex. One factor that affects the relationship between fat and health is how well adipose tissue is vascularized. Any new tissue that forms in the body needs to be vascularized to ensure its blood supply, and fat is no exception.
Clearmind Medicine Inc. has released promising preclinical results demonstrating efficacy of its psychedelic-derived drug candidate MEAI for treating obesity and metabolic syndrome.
Metabolic health is at an odd juncture. With the advent of glucagon-like peptide (GLP-1) agonists, pharmacologically induced weight loss has matured into a viable therapeutic option at long last. And research into the drug class is continuing apace.
Metabolic health is at an odd juncture. With the advent of glucagon-like peptide (GLP-1) agonists, pharmacologically induced weight loss has matured into a viable therapeutic option at long last. And research into the drug class is continuing apace.
A recent Epigen Biosciences Inc. patent describes ribosomal protein S6 kinase β (p70S6K) inhibitors reported to be useful for the treatment of diabetes, autism spectrum disorders, fibrosis, fragile X syndrome, liver diseases and nonalcoholic steatohepatitis (NASH).
Metabolic health is at an odd juncture. With the advent of glucagon-like peptide (GLP-1) agonists, pharmacologically induced weight loss has matured into a viable therapeutic option at long last. And research into the drug class is continuing apace.
RSS
